Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
Pulnovo Medical has completed a $100 million strategic financing round led by Medtronic, with participation from existing and new investors. The funding will support the company's clinical development, global regulatory submissions, and commercialization of its Pulmonary Artery Denervation (PADN) System.
Pulnovo Medical has secured $100 million in strategic financing led by Medtronic. The funding will support the company's clinical development and global commercialization of its Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy for treating Pulmonary Hypertension and Heart Failure. Pulnovo has performed approximately 1,500 PADN procedures globally and secured regulatory approvals in seven countries. The company is advancing commercialization across the European Union, Middle East, and China. In the US, Pulnovo has received FDA Breakthrough Device designation and initiated two Investigational Device Exemption (IDE) trials. The financing will also support the company's global leadership expansion, with Andre Xiao joining as Chief Strategy Officer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.